Biogen Buys Apellis for $5.6 Billion: Two New Drugs Supercharge Growth in Rare Diseases & Kidney Care

Biogen is acquiring Apellis for $5.6 billion, adding two approved drugs (Syfovre & Empaveli) for eye disease and rare kidney conditions. Boosts growth and nephrology pipeline.